Medicare Rule Brings More Drug Price Transparency To Part D
Executive Summary
CMS has decided to implement a new definition of "negotiated prices" under the Medicare Part D drug benefit that it believes will bring a new level of transparency to pricing in the program
You may also be interested in...
Part D Drug Pricing Change Would Affect Commercial Plans, PBMs Say
The Pharmaceutical Care Management Association is arguing that CMS' plan to redefine the allowable cost for drugs will have a negative impact not only on Medicare Part D prescription plans, but on commercial plans as well
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.